Drug Approval | April 28, 2024
Jubilant Pharmova announces completion of USFDA audit of Radiopharmaceuticals manufacturing facility at Montreal
The USFDA has issued 5 observations pursuant to the completion of audit
The USFDA has issued 5 observations pursuant to the completion of audit
With the receipt of the EIR, the inspection stands successfully closed.
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Harbour BioMed brings advanced antibody discovery platforms to the table
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Subscribe To Our Newsletter & Stay Updated
